CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We are very excited to launch our new website! Please take a few moments to click around and explore...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
This is the first update to the original CTS communication distributed on July 6th. As previously co...